A B S T R A C T The recent use of vasodilators to improve ventricular function in acute myocardial infarction led us to investigate the effects of nitroglycerin, nitroprusside, and phentolamine on coronary collateral flow. Dogs were studied 2-4 wk after an ameroid constrictor was placed around the left anterior descending (LAD) coronary artery. Retrograde flow and peripheral coronary pressure were measured from a cannula inserted in the LAD distal to the ameroid. Systemic arterial pressure was held constant by an aortic cuff. When administered intracoronary (i.c.), nitroglycerin, 0.3-100 ,ug/min, or nitroprusside, 3-100 ,ug/min, produced quantitatively similar, dose-dependent increases in retrograde flow. Neither drug, i.c., changed peripheral coronary pressure. Nitroglycerin, 3-300,g/min, intravenous (i.v.), produced dose-dependent increases in retrograde flow; nitroprusside, i.v., increased retrograde flow only in high doses (100-300 ,ug/min). Nitroglycerin and nitroprusside, i.v., produced similar increases in peripheral coronary pressure. Phentolamine, 1-300 ,ug/min, i.v., decreased retrograde flow, and did not change peripheral coronary pressure. Nitroprusside was considerably more potent than nitroglycerin in decreasing systemic arterial pressure and in reducing total coronary resistance. Thus, (a) although i.c. nitroglycerin and nitroprusside produce similar effects on collateral function, i.v. nitroglycerin is more effective than i.v. nitroprusside in augmenting collateral flow; (b) phentolamine has deleterious effects on collateral function; and (c) the relative vasodilator potencies of nitroglycerin and nitroprusside vary in different vascular beds; thus, for a given reduction in systemic
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INTRODUCTION
Reducing the impedance to left ventricular ejection by administration of such vasodilators as nitroglycerin (1, 2) , nitroprusside (3, 4) , or phentolamine (4, 5) has been shown to result in hemodynamic improvement in patients with acute myocardial infarction. However, an additional goal of vasodilator therapy in patients with acute myocardial infarction is the reduction in ischemic injury. Vasodilators might lessen ischemia through any of several mechanisms. Reduced ventricular filling would decrease wall tension and lower myocardial oxygen requirements. Decreased wall tension could also reduce intramural coronary artery compression and thereby contribute to an increase in collateral flow. Furthermore, vasodilators may directly increase collateral blood flow. Although it has been shown that nitroglycerin has the capacity to reduce ischemia (2, (6) (7) (8) (9) (10) and to increase collateral blood flow (11) (12) (13) , similar actions have not been demonstrated for other vasodilators currently being employed clinically. Indeed, recent evidence' suggests that nitroprusside, in contrast to nitroglycerin, may actually increase the degree of myocardial ischemia present during acute myocardial infarction (14) .
Because augmentation of collateral blood flow probably plays an important role in the alleviation of ischemic injury, the present investigation was under- 18 -26 kg were studied. The experimental procedure has been described in detail in a separate communication (13) . Briefly, an ameroid constrictor was placed around the left anterior descending (LAD)2 coronary artery, resulting in gradual occlusion of the artery; 2-4 wk were allowed for development of collateral vessels. At the time of study, the dogs were anesthetized with sodium pentobarbital, 40 mg/kg, i.v. The experimental preparation is shown in Fig. 1 For all these drugs, systemic arterial vasodilator effects were counteracted by inflation of the aortic cuff, so that systemic arterial pressure did not change with increasing drug concentration. Thus, under conditions of constant coronary perfusion pressure, i.v. nitroglycerin and nitroprusside, but not phentolamine, produced increases in the indices of collateral function. Furthermore, i.v. nitroglycerin enhanced collateral function at lower doses than did nitroprusside. To determine whether this difference reflected merely a different potency or a differing site of action for the two drugs, the effects of nitroglycerin and nitroprusside were further tested.
Effects of intracoronary nitroglycerin and nitroprusside on retrograde flow and peripheral coronary pressure. Nitroglycerin, 0.3-100 ,ug/min, i.c., and nitroprusside, 0.3-100 ,Lg/min, i.c., produced dosedependent increases in retrograde flow (Fig. 3) . The nitroglycerin-induced increases in retrograde flow were significant (P < 0.05) beginning at 0.3 jig/min; the nitroprusside-induced increases, at 3 ,ug/min. The nitroprusside-induced increments in retrograde flow were less than nitroglycerin-induced increments for any given dose, but the difference between the two was not significant. Neither drug, i.c., changed peripheral coronary pressure (Fig. 3) . Also, neither drug, i.c., significantly altered left atrial pressure.
Comparison of nitroglycerin-and nitroprusside-induced changes in resistance in different vascular beds. Although intracoronary nitroglycerin, 0. ,ug/min, and intracoronary nitroprusside, 0.3-100 lg/ min, produced quantitatively similar decreases in coronary collateral resistance (Fig. 4A) , nitroprusside was significantly more potent in reducing total left coronary resistance (Fig. 4B) . These changes in collateral and coronary resistance were determined under conditions of constant arterial pressure. In a separate study, arterial pressure was allowed to fall with increasing concentrations of i.v. nitroglycerin and nitroprusside, and total peripheral resistance was calculated (Fig. 4C) . The two drugs appear to have a similar threshold dose (between 30 and 100 ,ug/min); however, the slope of the nitroprusside curve for the reduction in total peripheral resistance was considerably steeper. Thus, whereas nitroprusside was more potent than nitroglycerin in reducing total (A mm Hg) from peripheral resistance and total coronary resistance, the two drugs administered i.c. produced equivalent effects on collateral resistance. The selective effect of nitroglycerin on collateral resistance was more marked when i.v. nitroglycerin and nitroprusside were compared. As shown in Fig. 5A , i.v. nitroglycerin was more effective than i.v. nitroprusside in reducing collateral resistance (P < 0.05 at 10 and 30 ,u g/min). This order of potency (nitro- (6) and in dogs with preexisting multivessel coronary occlusive disease (8) . When administered with methoxamine during acute coronary occlusion (the latter drug given to abolish nitroglycerin's effects on arterial pressure and heart rate), it attenuates the loss of myocardial creatine phosphokinase (7) and reduces the incidence of ventricular fibrillation (16) . Nitroglycerin also lowers ST segment elevation in acute myocardial infarction in man (2, 9, 10) . Although the mechanism of nitroglycerin's protective action is not fully understood, it is likely that the beneficial effects are partially due to both a reduction in myocardial oxygen requirements and an enhancement of coronary collateral blood flow. Evidence for the latter mechanism is found in studies demonstrating that nitroglycerin augments coronary collateral function in dogs (11, 13, and footnote 3) and man (12, 17) . Diminution of ischemic injury with nitroprusside or phentolamine, however, has not been demonstrated. Our results suggest that phentolamine might be less effective than either nitroglycerin or nitroprusside in reducing ischemic damage because it failed to augment collateral flow. Also, in recent studies comparing the effects of nitroglycerin and nitroprusside on ischemic injury during acute coronary occlusion in the dog, ST segment elevation was reduced by nitroglycerin but increased by nitroprusside (14 and footnote 4), and regional coronary flow was increased by nitroglycerin but reduced by nitroprusside (14) . The results of the present study suggest that these contrasting effects on ischemic injury might well be due to the fact that nitroglycerin has a different potency spectrum of vasodilator activity in various vascular beds than does 3 Smith, H. J., R. A. Goldstein, K. M. Kent, R. Aamodt, and S. E. Epstein. Reduction of myocardial ischemia by nitroglycerin and methoxamine: mechanisms of action. Submitted for publication. 
nitroprusside. These differences are complex, but probably are best understood by considering separately the direct and the indirect effects of these drugs on the coronary circulation. The direct effects of nitroglycerin and nitroprusside on the coronary circulation were determined by intracoronary infusion ofthe drugs. When administered in this manner, nitroglycerin and nitroprusside produced quantitatively similar dose-dependent decreases in coronary collateral resistance; however, nitroprusside was considerably more potent than nitroglycerin in decreasing total coronary arterial resistance. Likewise, nitroprusside was more potent than nitroglycerin in lowering systemic vascular resistance. Thus, the relative direct vasodilator potencies of nitroglycerin and nitroprusside are not the same for the three vascular beds studied: nitroprusside = nitroglycerin in the coronary collateral circulation, but nitroprusside > nitroglycerin in the coronary and peripheral arterial circulations.
These differences have important implications. First, if the drugs are administered in doses that produce similar decreases in arterial pressure, a relatively higher dose of nitroglycerin would be required to produce any given decrease in systemic arterial pressure; this would result in a greater reduction in collateral resistance than that achieved by the lower dose of nitroprusside. Second, the large reduction in total coronary resistance produced by nitroprusside probably was due largely to dilatation of coronary arterioles, because Winbury et al. (18) have shown that the contribution to total coronary arterial resistance of the large coronary arteries is small compared to the resistance offered by coronary arterioles (large coronary arteries contribute only about 5% of the total coronary resistance). Nitroprusside, by preferentially dilating coronary arterioles, under certain conditions, could predispose to changes that would lead to a coronary steal situation. For example, nitroprusside enhanced collateral function in our model, as indicated by an increase in retrograde flow. However, under conditions of myocardial ischemia and proximal narrowing of the coronary artery supplying the collateral vessels, nitroprusside-induced dilatation of the arterioles supplying nonischemic myocardium could reduce pressure within the narrowed artery. This would necessarily reduce the pressure at the origin of the collateral vessels, and thereby reduce collateral flow; i.e., there would be a redistribution of blood from ischemic to nonischemic regions. Third, nitroglycerin did not cause any substantial effect on total coronary resistance, a finding compatible with the studies ofFam and McGregor (19) 
